New ASAM youth criteria redefine SUD care with brain-stage levels, chronic monitoring, detox safety, and family-centered support.
Roueen Rafeyan, MD, DFAPA, FASAM
Advertisement
Dr Rafeyan is chief medical officer of the Gateway Foundation; an assistant professor of psychiatry at Northwestern University Feinberg School of Medicine in Chicago, Illinois; and the Psychiatric Times substance use section editor.
Articles by Roueen Rafeyan, MD, DFAPA, FASAM
Learn more about cannabis use and social media addiction in this month's Special Report!
The Psychiatric Times Substance Use Section Editor reflects on the theme of the 2024 Annual Meeting, plus what he is most excited about in psychiatry.
Psychiatric Times® Substance Use Section Editor Roueen Rafeyan, MD, DFAPA, FASAM, weighs in.
Psychiatric Times’ Substance Use Section Editor weighs in on the FDA approval of the first naloxone product for nonprescription use.
Clinicians are often busier than usual during the holidays. How can you find the time to spend quality time with your loved ones?
Advertisement
Latest Updated Articles
HHS $28 Million Grant Funding: What’s Next for SUD Treatment?February 20th 2024
Advertisement
Advertisement
Trending on Psychiatric Times
1
Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
2
FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults
3
How Can Sleep Disruption Trigger Mood Episodes?
4
Evaluating Transdermal Asenapine in Schizophrenia
5